Vigil Neuroscience (NASDAQ:VIGL) Announces Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Vigil Neuroscience (NASDAQ:VIGL) posted its earnings results on Thursday. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08), Zacks reports.

Vigil Neuroscience Trading Down 10.2 %

Vigil Neuroscience stock opened at $2.11 on Friday. The firm has a 50-day moving average price of $2.34 and a 200-day moving average price of $2.80. The firm has a market capitalization of $86.25 million, a PE ratio of -1.02 and a beta of 1.82. Vigil Neuroscience has a 12-month low of $1.49 and a 12-month high of $6.06.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, January 23rd. William Blair assumed coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating for the company. Finally, JMP Securities reiterated a “market outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.